About Liniment Pharma Private Limited
Data last updated: 09 February 2026
Liniment Pharma Private Limited is a private limited company based in Jaipur, Rajasthan, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 February 2018, the company has been in operation for over 8 years.
Registered with ROC Jaipur under CIN U24304RJ2018PTC060344.
Capital: an authorised share capital of ₹10 Lakh and a paid-up capital of ₹2.44 Lakh. It is led by directors Rohit Bafna and Aastha Dusad.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No. – 38 Shankar Colony Naya Kheda Ambabari, Jaipur, Rajasthan, India – 302039.
As per the financials filed for FY 2024, the company reported a revenue of ₹1.64 Cr, a growth of 21% compared to the previous year.
The company has a workforce of approximately 10 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Meddelivery.
For more details, the company can be reached via its website meddelivery.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Apps
-
Registered AddressPlot No. – 38 Shankar Colony Naya Kheda Ambabari, Jaipur, Rajasthan, India – 302039
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Liniment Pharma Private Limited
Liniment Pharma Private Limited operates one associated brand: MEDdelivery. These brands represent Liniment Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Retail pharma procurement is enabled via hyperlocal e-commerce platform. | meddelivery.in |
Competitors & Alternatives of Liniment Pharma Private Limited
Brands and companies operating in the same space as Liniment Pharma Private Limited include API Holdings, giftHEALTH, Pharmacist Bang and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
API Holdings
|
Digital healthcare tools are offered for pharmacies and clinics management. | Mumbai, India, India | 2012 |
giftHEALTH
|
Provider of supply chain management platform | Columbus, United States, United States | 2009 |
Pharmacist Bang
|
A mobile marketplace is provided for pharmacists and pharmaceutical companies. | Guangzhou, China, China | 2015 |
Biddano
|
Cloud-based supply chain management is provided for pharmacies and hospitals. | Pune, India, India | 2016 |
Remedial Health
|
Supply chain management software is provided for pharmacies and insurers. | Newark, United States, United States | 2020 |
RELATABLE
|
Healthcare product supply chains are managed via a dedicated platform. | Nashville, United States, United States | 2016 |
PharmacyMarts
|
Online supply chain management platform for medical suppliers | Egypt | 2020 |
DrugStoc
|
Provider of procurement platform for pharmacies, clinics, and healthcare organizations | Ikeja, Nigeria, Nigeria | 2015 |
Yaopin Zhongduanwang
|
Operates a B2B e-commerce platform for pharmaceuticals. | Chengdu, China, China | 2010 |
Business Activity of Liniment Pharma Private Limited
Liniment Pharma Private Limited is engaged in the principal business activity of transport and storage, with detailed activities including services incidental to land, water & air transportation.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| H | Transport and storage | H5 | Services incidental to land, water & air transportation | ********* |
Auditor Details of Liniment Pharma Private Limited
Liniment Pharma Private Limited is audited by R SOGANI & ASSOCIATES for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| R SOGANI & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Liniment Pharma Private Limited
Liniment Pharma Private Limited is currently managed by 2 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rohit Bafna | Director | 26 Feb 2018 | 8 Years 4 Months | Current |
|
Aastha Dusad
Also directs:
United Suppliers Solutions Private Limited
|
Director | 26 Feb 2018 | 8 Years 4 Months | Current |
Financials of Liniment Pharma Private Limited FY 2025 filings available
Liniment Pharma Private Limited reported revenue of ₹1.64 Cr (up 21% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Liniment Pharma Private Limited
As of FY 2022, Liniment Pharma Private Limited's shareholding pattern shows 73.97% by promoters, 8.36% by domestic institutional investors (DII), 17.67% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Liniment Pharma Private Limited
Liniment Pharma Private Limited has 1 subsidiary company. This group structure data is as of FY 2022. The corporate group structure reflects Liniment Pharma Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| United Suppliers Solutions Private Limited | U63031RJ2021PTC076980 |
**.**%
|
Showing major subsidiaries. Total: 1.
Charges & Borrowings Liniment Pharma Private Limited
Liniment Pharma Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Liniment Pharma Private Limited
Liniment Pharma Private Limited has a workforce of 10 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Liniment Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Liniment Pharma Private Limited
GSTIN & GST Filing Data of Liniment Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Liniment Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Liniment Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Liniment Pharma Private Limited
MSME Payment Delays by Liniment Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Liniment Pharma Private Limited
Subsidiaries & Group Companies of Liniment Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Liniment Pharma Private Limited with ownership details.
MCA Filings & Documents of Liniment Pharma Private Limited
MCA Filings & Documents of Liniment Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Liniment Pharma Private Limited
Frequently Asked Questions about Liniment Pharma Private Limited
Liniment Pharma Private Limited is an active private limited company in the pharma sector based in Jaipur, Rajasthan, India. It was incorporated on 26 February 2018 (8+ years old) and is registered under CIN U24304RJ2018PTC060344. The company has 10 employees.
Liniment Pharma Private Limited reported revenue of ₹1.64 Cr for FY 2024 (up 21.00% YoY).
The current directors of Liniment Pharma Private Limited are:
The primary industry of Liniment Pharma Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Liniment Pharma Private Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Liniment Pharma Private Limited can be reached at the registered office: Plot No. – 38 Shankar Colony Naya Kheda Ambabari, Jaipur, Rajasthan, India – 302039, or through the website meddelivery.in.